CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease.

Melanoma patients who got an mRNA vaccine for the virus saw median survival times double.

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Vaccine manufacturing is challenged by stringent global regulations, essential for ensuring safety and efficacy, with ...

Vaccines train the body's defenses to fight infections safely. Learn how vaccines work, how the immune system responds, and ...

According to Nova One Advisor, the global RNA therapeutics market size is calculated at USD 8.55 billion in 2025 and is ...

The department said Suzman’s participation highlights the foundation’s long-standing partnership with Biovac and commitment ...